Stage
Unattributed VC | AliveTotal Raised
$3MLast Raised
$2.5M | 2 yrs agoAbout Longevica
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Longevica's Product Videos


Longevica's Products & Differentiators
Health Base
The Longevica Health Base is a home health monitoring center that supports you to better adhere to chronic medication treatments and gain easier access to digital health tools to promote healthy aging and daily betterment of living. Caregivers will also gain a peace of mind that their loved ones are improving lifestyle wellness and in stable health.
Longevica Patents
Longevica has filed 5 patents.
The 3 most popular patent topics include:
- Chelating agents
- Health insurance
- Managed care

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
10/18/2017 | 5/19/2020 | Chelating agents, Enzymes, Metabolism, Gastrointestinal tract disorders, EC 2.1.1 | Grant |
Application Date | 10/18/2017 |
---|---|
Grant Date | 5/19/2020 |
Title | |
Related Topics | Chelating agents, Enzymes, Metabolism, Gastrointestinal tract disorders, EC 2.1.1 |
Status | Grant |
Latest Longevica News
May 29, 2023
Princeton, New Jersey | May 29, 2023 10:30 AM Eastern Daylight Time Longevica , a New Jersey-based science-driven company committed to uncovering the mechanisms of life extension, is actively seeking funding to support its groundbreaking research. With a team of dedicated scientists and philanthropists, Longevica relies on scientific data derived from fundamental experiments and comprehensive models to drive its mission. Established in 2009, Longevica's vision is to slow down aging, postpone age-related diseases, and ultimately eliminate them. Longevica’s research takes a contrarian approach aimed at identifying the mechanisms of life extension. The company embarked on an ambitious experiment involving the largest array of well-characterized pharmacological compounds in mice, making it the largest study conducted on long-lived mice to date. The study carried out at the renowned Jackson Laboratory in California, involved 20,000 long-lived female mice and examined the effects of 1,033 pharmacological compounds, for example Magnesium, Aspirin and so on. According to the company, the experiment proved to be a resounding success. Furthermore, through extensive big data analysis, Longevica identified two particular classes of compounds out of the total 62 that demonstrated a statistically significant correlation with life extension. This breakthrough provided crucial insights into the existence of mechanisms underlying life extension. Building upon these remarkable findings, the Longevica team dedicated the subsequent six years to the study of these two compound classes. Their research focused on understanding the mechanisms of action and the historical applications of these compounds in human medicine. As a result, the team in 2019-2021 established valid hypotheses regarding two mechanisms of life extension, with further details currently being specified. Both mechanisms aim to combat harmful compounds accumulation, leading to improved health and extended lifespan. These results were a surprise to all that were part of this experiment, truly showing the lack of knowledge and expectations we have regarding evolution and length of lifespan. The core paradigm of Longevica's life extension approach revolves around reducing “toxins”, thereby mitigating age-related diseases and promoting longevity. Following 14 years of research including their mice experiment and 15 million dollars in financing, Longevica is now poised to complete its aging research. “The truth is that we as humanity have a mission. After years of research, we still don’t understand the mechanisms that would enable us to move the survival curve to the right, meaning extending life span, even in mice. This research will be able to answer many if not all questions regarding life extension, bringing it out of a world of myth into reality. We plan on being able to turn our focus towards human life extension in our future research.” says Alexander Chikunov, founder of Longevica who provided all funds for this stage of research. Media contact:
Longevica Frequently Asked Questions (FAQ)
Where is Longevica's headquarters?
Longevica's headquarters is located at 7 Deerpark Drive, Monmouth Junction.
What is Longevica's latest funding round?
Longevica's latest funding round is Unattributed VC.
How much did Longevica raise?
Longevica raised a total of $3M.
Who are the investors of Longevica?
Investors of Longevica include Xploration Capital, Foundation Venture Capital Group and Alexander Chikunov.
Who are Longevica's competitors?
Competitors of Longevica include Aerie, Cerecin, Athelas, 100Plus, Acumen Pharmaceuticals, Hero Health, Philogen, Endocyte, BaroFold, Biosceptre International and 46 more.
What products does Longevica offer?
Longevica's products include Health Base and 2 more.
Compare Longevica to Competitors
Anaborex Anaborex is an early stage biotechnology company developing drugs for the treatment of the wasting syndrome many cancer patients experience towards the late stages of their disease.

Immunservice is a biopharmaceutical company addressing orphan disease indications as well as large market indication areas, especially those of high unmet medical need.Immunservice's biomimetic approach translates human immune hormones into well tolerated and highly effective marketable drugs that improve survival and quality of life in patients.Biomimetic therapy has the clear potential to cure patients with cancer, even those who are in urgent need and have little or no treatment alternatives.

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Hunter-Fleming is a biopharmaceutical company developing new medicines to treat neurological and cardiovascular disorders. The company focus is on unmet patient needs in dementias such as Alzheimer's disease, as well as other important conditions such as neuropathic pain, head and spinal cord injuries and myocardial infarction.
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.